Fulvestrant Followed by Everolimus Plus Exemestane vs Examestane and Everolimus Followed by Fulvestrant in Postmenopausal Women With HR+ and HER2- Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) Previously Treated With NSAI

Trial Profile

Fulvestrant Followed by Everolimus Plus Exemestane vs Examestane and Everolimus Followed by Fulvestrant in Postmenopausal Women With HR+ and HER2- Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) Previously Treated With NSAI

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Everolimus (Primary) ; Exemestane; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms FEVEX
  • Sponsors Oncotech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 08 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top